(Q44058016)

29 November 2017

title

Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity (English)

1 reference

29 November 2017

3

1 reference

29 November 2017

Saghir Akhtar

1

0 references

author name string

Debbie Dunnion

2

1 reference

29 November 2017

John Ackroyd

4

1 reference

29 November 2017

Mike Bibby

5

1 reference

29 November 2017

John Double

6

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

29 November 2017

published in

Biochemical Pharmacology

1 reference

29 November 2017

volume

63

1 reference

29 November 2017

issue

12

1 reference

29 November 2017

page(s)

2187-2195

1 reference

The cellular delivery of antisense oligonucleotides and ribozymes

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

The delivery of antisense therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Selecting optimal antisense reagents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

In vivo studies with antisense oligonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Selection of a Suppressor Mutation That Restores Affinity of an Oligonucleotide Inhibitor for Thrombin Using in Vitro Genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Selection of single-stranded DNA molecules that bind and inhibit human thrombin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Cellular uptake properties of a 2'-amino/2'-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Synthetic 2'-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Pharmacological characterization of a receptor for calcitonin gene-related peptide on rat, L6 myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Immune effects and mechanisms of action of CpG motifs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

CpG motifs in bacterial DNA trigger direct B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

The role of the epidermal growth factor receptor in human gliomas: II. The control of glial process extension and the expression of glial fibrillary acidic protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glycolide) microsphere formulations for potential combination therapy in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2900985-1

10.1016/S0006-2952(02)00985-1

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference